Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge.

Cox F, van der Fits L, Abbink P, Larocca RA, van Huizen E, Saeland E, Verhagen J, Peterson R, Tolboom J, Kaufmann B, Schuitemaker H, Barouch DH, Zahn R.

PLoS One. 2018 Aug 24;13(8):e0202820. doi: 10.1371/journal.pone.0202820. eCollection 2018.

2.

Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients.

Boonk SE, Zoutman WH, Marie-Cardine A, van der Fits L, Out-Luiting JJ, Mitchell TJ, Tosi I, Morris SL, Moriarty B, Booken N, Felcht M, Quaglino P, Ponti R, Barberio E, Ram-Wolff C, Jäntti K, Ranki A, Bernengo MG, Klemke CD, Bensussan A, Michel L, Whittaker S, Bagot M, Tensen CP, Willemze R, Vermeer MH.

J Invest Dermatol. 2016 Jul;136(7):1364-1372. doi: 10.1016/j.jid.2016.01.038. Epub 2016 Feb 28.

3.

EPHA4 is overexpressed but not functionally active in Sézary syndrome.

Hameetman L, van der Fits L, Zoutman WH, Out-Luiting JJ, Siegal G, de Esch IJ, Vermeer MH, Tensen CP.

Oncotarget. 2015 Oct 13;6(31):31868-76. doi: 10.18632/oncotarget.5573.

4.

Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment.

Halkes CJM, Zoutman WH, van der Fits L, Jedema I, Vermeer MH.

J Invest Dermatol. 2015 Apr;135(4):1199-1202. doi: 10.1038/jid.2014.501. Epub 2014 Nov 28. No abstract available.

5.

Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

van der Fits L, Out-Luiting JJ, Tensen CP, Zoutman WH, Vermeer MH.

J Invest Dermatol. 2014 Oct;134(10):2639-2647. doi: 10.1038/jid.2014.199. Epub 2014 Apr 22.

6.

Caspase-14-deficient mice are more prone to the development of parakeratosis.

Hoste E, Denecker G, Gilbert B, Van Nieuwerburgh F, van der Fits L, Asselbergh B, De Rycke R, Hachem JP, Deforce D, Prens EP, Vandenabeele P, Declercq W.

J Invest Dermatol. 2013 Mar;133(3):742-750. doi: 10.1038/jid.2012.350. Epub 2012 Sep 27.

7.

A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.

van der Fits L, Rebel HG, Out-Luiting JJ, Pouw SM, Smit F, Vermeer KG, van Zijl L, Tensen CP, Weijer K, Vermeer MH.

Exp Dermatol. 2012 Sep;21(9):706-9. doi: 10.1111/j.1600-0625.2012.01556.x.

PMID:
22897578
8.

NOTCH1 signaling as a therapeutic target in Sézary syndrome.

van der Fits L, Qin Y, Out-Luiting JJ, Vermeer KG, Whittaker S, van Es JH, Tensen CP, Vermeer MH.

J Invest Dermatol. 2012 Dec;132(12):2810-7. doi: 10.1038/jid.2012.203. Epub 2012 Jun 21.

9.

Deep-sequencing analysis reveals that the miR-199a2/214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sézary syndrome.

Qin Y, Buermans HP, van Kester MS, van der Fits L, Out-Luiting JJ, Osanto S, Willemze R, Vermeer MH, Tensen CP.

J Invest Dermatol. 2012 May;132(5):1520-2. doi: 10.1038/jid.2011.481. Epub 2012 Feb 16. No abstract available.

10.

Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.

van der Fits L, Out-Luiting JJ, van Leeuwen MA, Samsom JN, Willemze R, Tensen CP, Vermeer MH.

J Invest Dermatol. 2012 Feb;132(2):440-7. doi: 10.1038/jid.2011.293. Epub 2011 Sep 22.

11.

GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4.

Rácz E, Kurek D, Kant M, Baerveldt EM, Florencia E, Mourits S, de Ridder D, Laman JD, van der Fits L, Prens EP.

PLoS One. 2011;6(5):e19806. doi: 10.1371/journal.pone.0019806. Epub 2011 May 17.

12.

Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways.

Rácz E, Prens EP, Kurek D, Kant M, de Ridder D, Mourits S, Baerveldt EM, Ozgur Z, van IJcken WF, Laman JD, Staal FJ, van der Fits L.

J Invest Dermatol. 2011 Jul;131(7):1547-58. doi: 10.1038/jid.2011.53. Epub 2011 Mar 17.

13.

A restricted clonal T-cell receptor αβ repertoire in Sézary syndrome is indicative of superantigenic stimulation.

van der Fits L, Sandberg Y, Darzentas N, Zoutman WH, Tielemans D, Wolvers-Tettero IL, Vermeer MH, Langerak AW.

Br J Dermatol. 2011 Jul;165(1):78-84. doi: 10.1111/j.1365-2133.2011.10308.x. Epub 2011 Jun 2.

PMID:
21410672
14.

miRNA expression profiling of mycosis fungoides.

van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, van der Fits L, van Doorn R, Vermeer MH, Willemze R, Tensen CP, Lawrie CH.

Mol Oncol. 2011 Jun;5(3):273-80. doi: 10.1016/j.molonc.2011.02.003. Epub 2011 Feb 24.

15.

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, Hodges E, Vermeer M, Packham G.

Br J Pharmacol. 2011 Apr;162(7):1590-602. doi: 10.1111/j.1476-5381.2010.01188.x.

16.

Narrowband ultraviolet B inhibits innate cytosolic double-stranded RNA receptors in psoriatic skin and keratinocytes.

Rácz E, Prens EP, Kant M, Florencia E, Jaspers NG, Laman JD, de Ridder D, van der Fits L.

Br J Dermatol. 2011 Apr;164(4):838-47. doi: 10.1111/j.1365-2133.2010.10169.x.

PMID:
21143460
17.

MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.

van der Fits L, van Kester MS, Qin Y, Out-Luiting JJ, Smit F, Zoutman WH, Willemze R, Tensen CP, Vermeer MH.

J Invest Dermatol. 2011 Mar;131(3):762-8. doi: 10.1038/jid.2010.349. Epub 2010 Nov 18.

18.

Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis.

Rácz E, de Leeuw J, Baerveldt EM, Kant M, Neumann HA, van der Fits L, Prens EP.

Lasers Surg Med. 2010 Mar;42(3):201-10. doi: 10.1002/lsm.20898.

PMID:
20333742
19.

Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.

van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E.

J Immunol. 2009 May 1;182(9):5836-45. doi: 10.4049/jimmunol.0802999.

20.

Polymorphisms in the interferon regulatory factor-1 promoter are not associated with psoriasis and do not influence IFN-alpha-induced Th1 polarization.

Van Der Fits L, Kant M, Van Der Wel LI, Prens EP.

J Interferon Cytokine Res. 2007 Oct;27(10):841-6.

PMID:
17970693
21.

IFN-alpha enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis.

Prens EP, Kant M, van Dijk G, van der Wel LI, Mourits S, van der Fits L.

J Invest Dermatol. 2008 Apr;128(4):932-8. Epub 2007 Oct 11.

22.

[New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].

Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.

Ned Tijdschr Geneeskd. 2006 May 13;150(19):1065-70. Review. Dutch.

PMID:
16733982
23.

Peptidoglycan and peptidoglycan-specific Th1 cells in psoriatic skin lesions.

Baker BS, Laman JD, Powles A, van der Fits L, Voerman JS, Melief MJ, Fry L.

J Pathol. 2006 Jun;209(2):174-81.

PMID:
16493599
24.

[The pathogenesis of inflammatory dermatoses, especially psoriasis].

Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.

Ned Tijdschr Geneeskd. 2006 Jan 28;150(4):179-83. Review. Dutch.

PMID:
16471231
25.

Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2.

Zhang Y, van der Fits L, Voerman JS, Melief MJ, Laman JD, Wang M, Wang H, Wang M, Li X, Walls CD, Gupta D, Dziarski R.

Biochim Biophys Acta. 2005 Aug 31;1752(1):34-46.

PMID:
16054449
26.

Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions.

Companjen A, van der Wel L, van der Fits L, Laman J, Prens E.

Eur Cytokine Netw. 2004 Jul-Sep;15(3):210-6.

27.

Zinc finger proteins act as transcriptional repressors of alkaloid biosynthesis genes in Catharanthus roseus.

Pauw B, Hilliou FA, Martin VS, Chatel G, de Wolf CJ, Champion A, Pré M, van Duijn B, Kijne JW, van der Fits L, Memelink J.

J Biol Chem. 2004 Dec 17;279(51):52940-8. Epub 2004 Oct 1.

28.

In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered.

van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC.

J Invest Dermatol. 2004 Jan;122(1):51-60. Erratum in: J Invest Dermatol. 2004 Aug;123(2):415.

29.

Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2).

van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC.

J Pathol. 2003 Jan;199(1):107-14.

PMID:
12474233
30.
33.
34.
35.
36.

Effects of over-expression of strictosidine synthase and tryptophan decarboxylase on alkaloid production by cell cultures of Catharanthus roseus.

Canel C, Lopes-Cardoso MI, Whitmer S, van der Fits L, Pasquali G, van der Heijden R, Hoge JH, Verpoorte R.

Planta. 1998 Jul;205(3):414-9.

PMID:
9640666
37.

A site-specific recombinase is required for competitive root colonization by Pseudomonas fluorescens WCS365.

Dekkers LC, Phoelich CC, van der Fits L, Lugtenberg BJ.

Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7051-6.

Supplemental Content

Loading ...
Support Center